The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

The company now expects vaccine sales to decline by low ... while sales of its shot for respiratory syncytial virus, Arexvy, plunged by 72% year over year. In a presentation, GSK attributed ...

Arexvy performance was impacted by three factors ... so it's important Jemperli is now available to these patients. Zejula's growth continued in Q3 driven by U.S. pricing effects and high demand ...

TORONTO — Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults ...

GSK plc (LSE/NYSE: GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy ...

That means that if you haven’t gotten vaccines already, it’s time to put them on your to-do list. But which ones should you ...

GSK plc (LSE/NYSE: LON:GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy ... Final ...

Starting November 4, doses of the RSV immunization will also be available for infants and high-risk children up to 24 months ...

On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial ... for RSV-LRTD until additional data became available. Price Action: GSK stock is down 0.53% ...